In reversed-phase HPLC release testing of tablet, capsule, and granule formulations, acetonitrile functions as the organic mobile-phase modifier controlling retention, peak symmetry, and elution strength. The solvent is combined with aqueous buffer at volume ratios from 20:80 to 60:40, selected according to the API pKa and log P. HPLC-grade acetonitrile is specified because its UV cutoff near 190 nm and its low non-volatile residue permit photodiode array detection at wavelengths down to 210 nm without excessive baseline drift. The mixed mobile phase is filtered through a 0.22 µm nylon or PTFE membrane and degassed under vacuum before delivery through a binary pump. The column is a C18 stationary phase with a particle size between 1.8 µm and 5.0 µm, an internal diameter of 2.1 mm or 4.6 mm, and a length from 50 mm to 250 mm. System suitability is assessed according to USP <621>: tailing factor is not more than 2.0, theoretical plates are not less than 2000, and the relative standard deviation for five replicate injections is not more than 2.0%. Method validation follows ICH Q2(R2) for specificity, linearity, accuracy, and precision. For tablet and capsule content uniformity testing, a single dosage unit is crushed, extracted with an acetonitrile-containing diluent, clarified by filtration, and assayed against a reference standard. The resulting data support release under USP <905> for finished oral solid dosage forms. This application extends to granule-filled sachets when the granule mass is ground and extracted under the same mobile-phase-aligned diluent conditions.

What Limits Low-Wavelength Sensitivity in Dissolution Sample Diluents?

Dissolution testing of immediate-release tablet and capsule products produces aqueous samples that often require an organic diluent to maintain API solubility after withdrawal from the vessel. Acetonitrile is added to the filtered dissolution sample at a volume fraction between 10% and 40%, with the proportion matched to the initial mobile-phase composition to avoid peak splitting and injection solvent effects. The dissolution apparatus is operated at 37 °C ± 0.5 °C under USP <711>, using Apparatus 1 or Apparatus 2. A 5 mL aliquot is withdrawn, passed through a 0.45 µm PVDF syringe filter, and mixed with acetonitrile in a volumetric ratio that keeps the final organic content below the precipitation threshold for hydrophilic excipients. Low-wavelength detection from 210 nm to 230 nm is sensitive to UV-absorbing impurities; HPLC-grade acetonitrile with low UV background is therefore used. The chromatographic run uses a binary pump with a gradient from 5% to 90% acetonitrile over 10 min, followed by a 3 min re-equilibration. System suitability criteria follow USP <621> and are verified at the start of each set of dissolution injections. The terminal output is a dissolution profile for immediate-release tablets and capsules, with calibration standards prepared in the same acetonitrile-fortified diluent to maintain matrix equivalence during quantitation.

For assay extraction from granules and granule-coated tablet cores, acetonitrile is used as the stronger solvent component in acetonitrile-water diluents. A typical extraction solvent is 70:30 acetonitrile:water, with the ratio reduced to 40:60 for APIs of lower hydrophobicity. The granule sample is dispersed in water first to swell and break the binder, then a measured volume of acetonitrile is added, and the mixture is sonicated at 40 kHz for 10 min to 15 min in a closed container to limit evaporative loss. The slurry is transferred to a Class A volumetric flask, diluted to volume, and mixed by inversion. A portion is centrifuged at 3000 rpm for 5 min, and the clear supernatant is injected onto a C18 column maintained at 30 °C. If the granule contains a lipid-based binder, the acetonitrile fraction is increased to promote complete API dissolution. The method is validated for accuracy and precision under ICH Q2(R2), and the result is compared with the acceptance limits in USP <905>. Terminal finished product coverage includes granule-filled sachets, coated tablet cores prepared from granules, and hard gelatin capsule contents. Acetonitrile water miscibility and low residue after evaporation prevent extract interference with later LC detection.

Residual Solvent Verification by Headspace Gas Chromatography in Spray-Dried Granules

Acetonitrile remaining in spray-dried granules after solvent-based granulation is quantified by headspace GC-FID because the analyte is volatile and water-miscible. The acceptance criterion is derived from ICH Q3C(R8): acetonitrile is a Class 2 solvent with a permitted daily exposure of 4.1 mg/day and a concentration limit of 410 ppm in oral finished products. Sample preparation uses 500 mg of ground granule mass in a 20 mL headspace vial with 5 mL of diluent, followed by incubation at 80 °C for 30 min. The vial is pressurized and injected through a transfer line at 120 °C into a DB-624 column of dimensions 30 m × 0.32 mm × 1.8 µm. Helium is used as carrier gas at 1.5 mL/min, with a split ratio of 20:1 and FID at 260 °C. The oven program starts at 40 °C for 5 min, ramps at 20 °C/min to 240 °C, and holds for 5 min. Method validation follows ICH Q2(R2) for specificity, linearity from 50 ppm to 1000 ppm, and recovery between 90% and 110%. Quantitation is referenced to USP <467> as a general limit test framework, with the final acceptance limit based on the drug product daily dose. The terminal deliverable is a batch release residual-solvent certificate for spray-dried granules, coated tablets, and capsule formulations.

Preparative Reversed-Phase Purification of Injectable Peptide APIs Requires Acetonitrile Gradients With Post-Lyophilization Residual Control

In preparative HPLC purification of peptide APIs intended for injectable solution or lyophilized powder, acetonitrile is the organic eluent in reverse-phase systems. Mobile phase A is typically 0.1% trifluoroacetic acid in water, and mobile phase B is 0.1% trifluoroacetic acid in acetonitrile. The preparative column is a C18 stationary phase with dimensions 250 mm × 21.2 mm and particle size 10 µm. The flow rate is set at 40 mL/min, and the gradient is run from 18% to 38% mobile phase B over 40 min. Fractions are collected based on UV detection at 220 nm and confirmed by analytical HPLC. Acetonitrile is removed from pooled fractions by rotary evaporation at 40 °C under reduced pressure, followed by lyophilization. Residual acetonitrile in the final peptide API is measured by headspace GC-FID and must comply with ICH Q3C(R8) for parenteral products. The process is governed by ICH Q7 for active pharmaceutical ingredients, and the finished injectable is subject to FDA 21 CFR 211. The terminal products are injectable lyophilized peptide powders and injectable solutions after reconstitution. One operational boundary is that acetonitrile in the presence of trifluoroacetic acid at low pH can generate trifluoroacetyl adducts if the peptide contains free primary amines; the process therefore uses cold lyophilization and pH adjustment before drying to limit degradation.

Cleaning validation in multi-product tablet and injectable manufacturing lines uses acetonitrile as a swab extraction solvent when the target API is poorly water-soluble and the analytical finish is reversed-phase HPLC. The swab is pre-wetted with 50:50 acetonitrile:water, a surface area of 25 cm² is sampled, and the swab is extracted with 5 mL of the same solvent in a screw-cap vial. Recovery studies are performed by spiking API onto stainless steel, PTFE, and EPDM coupons at three loads: 0.1 µg/cm², 1.0 µg/cm², and 10 µg/cm². The extraction procedure is sonicated at 40 kHz for 10 min. Acceptance limits are calculated from the maximum allowable carryover and the shared equipment surface area, then quantitated by HPLC against a calibration curve bracketing the limit. The terminal deliverable is a cleaning validation report supporting compliance with FDA 21 CFR 211.67(b) and batch release for subsequent tablet, capsule, granule, and injectable products. If the API degrades in acetonitrile, published data for that specific configuration is limited; a forced degradation impurity profile is generated before the method is finalized. The same solvent system is used for rinse-water extraction in lower-risk equipment surfaces where direct swab contact is not possible.

When Acetonitrile Is Used as a Crystallization Antisolvent in Injectable-Grade API Manufacturing

Acetonitrile is applied as a controlled antisolvent in batch crystallization to reduce dissolved API concentration and to control particle size and polymorphic form. The API is dissolved in a primary solvent, and acetonitrile is added at a rate of 0.5 mL/min while the mixture is cooled from 50 °C to 5 °C at approximately 0.1 °C/min. The final antisolvent-to-solvent volume ratio ranges from 2:1 to 5:1. The slurry is filtered, and the cake is washed with pre-cooled acetonitrile before vacuum drying. Residual acetonitrile in the dried injectable-grade API is controlled to the ICH Q3C(R8) permitted daily exposure of 4.1 mg/day and the 410 ppm concentration limit, with tightened in-process limits applied when the product is a parenteral powder with a small daily dose. Particle size distribution is verified by laser diffraction, and the dried API is used for injectable suspension or solution after reconstitution. Operational boundaries include the risk of solvate formation; therefore, X-ray powder diffraction is used to confirm that the final polymorph is unchanged after drying. This application is limited to APIs that exhibit adequate chemical stability in acetonitrile at the processing temperature.